STERIS plc (STE) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals solid financial performance, with increased revenue and improved EBIT margins in key segments. Despite some margin declines due to tariffs, the overall outlook remains optimistic, supported by strong growth in Life Sciences and AST. The Q&A section highlights effective mitigation strategies for tariffs and positive market trends, such as capacity expansions. The increase in earnings and free cash flow guidance further supports a positive sentiment. However, the lack of major M&A and conservative cash flow guidance slightly temper the outlook, leading to a positive but not strong positive prediction.
Key Financial Performance
Total as-reported revenue Grew 9% year-over-year, driven by volume and 200 basis points of price.
Constant currency organic revenue Grew 8% year-over-year, driven by volume and 200 basis points of price.
Gross margin Declined 70 basis points year-over-year to 43.9%, due to increased tariffs and inflation, despite positive price and productivity.
EBIT margin Decreased 40 basis points year-over-year to 22.9%, mainly due to the decline in gross margin, partially mitigated by operating expense discipline.
Adjusted effective tax rate Decreased slightly to 24.2% from 24.5% year-over-year, driven by changes in geographic mix.
Adjusted net income from continuing operations $249.4 million, with a 9% increase year-over-year.
Earnings per diluted share from continuing operations $2.53, a 9% increase year-over-year.
Capital expenditures (first 9 months of fiscal 2026) $278.8 million.
Depreciation and amortization (first 9 months of fiscal 2026) $363.1 million.
Total debt at quarter end $1.9 billion, with gross debt to EBITDA at approximately 1.2x.
Free cash flow (first 9 months of fiscal 2026) $737.6 million, with year-over-year improvement driven by increased earnings and lower capital spending.
Healthcare constant currency organic revenue Grew 8% year-over-year, with 11% growth in service, 8% growth in consumables, and 7% growth in capital equipment revenue. Orders were down 1% year-to-date due to difficult comparisons to last year.
Healthcare EBIT margins Decreased 100 basis points year-over-year to 24.3%, as volume, pricing, and restructuring program benefits were offset by increased tariffs and inflation.
AST constant currency organic revenue Grew 8% year-over-year, with 9% growth in services and 103% growth in capital equipment revenue. Services benefited from stable medical device volumes, bioprocessing demand, and currency.
AST EBIT margins Increased 30 basis points year-over-year to 45.1%, as additional pricing and volume offset increases in labor and energy costs and unfavorable mix impact from strong capital growth.
Life Sciences constant currency organic revenue Increased 5% year-over-year, driven by 11% growth in consumables and 7% growth in capital equipment revenue.
Life Sciences margins Declined 20 basis points year-over-year, as volume and price were offset by tariffs and inflation.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Healthcare capital equipment revenue: Increased 7% for the quarter with backlog remaining over $400 million.
AST capital equipment revenue: Grew 103% for the quarter.
Life Sciences capital equipment revenue: Grew 7% with backlog holding over $100 million.
Healthcare service revenue: Grew 11% in the third quarter, continuing its streak of outperformance.
Healthcare consumables revenue: Grew 8% in the third quarter.
AST services revenue: Grew 9% for the quarter, benefiting from stable medical device volumes, bioprocessing demand, and currency.
Life Sciences consumables revenue: Grew 11% in the quarter.
Gross margin: Declined 70 basis points to 43.9% due to increased tariffs and inflation, despite positive price and productivity.
EBIT margin: Decreased 40 basis points to 22.9% of revenue, mainly driven by the decline in gross margin.
Free cash flow: Improved to $737.6 million for the first 9 months of fiscal 2026, driven by increased earnings and lower capital spending.
Fiscal 2026 outlook: Maintained outlook for 8%-9% as-reported revenue growth and 7%-8% constant currency organic revenue growth. Earnings outlook of $10.15 to $10.30 per share is also maintained, though the higher end is less likely due to $10 million more in anticipated tariffs.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Gross Margin Decline: Gross margin for the quarter declined by 70 basis points to 43.9%, primarily due to increased tariffs and inflation, which offset positive price and productivity gains.
EBIT Margin Decrease: EBIT margin decreased by 40 basis points to 22.9% of revenue, driven by the decline in gross margin despite operating expense discipline.
Tariff Impact: The company faced approximately $16 million in pretax tariff impact, primarily affecting the Healthcare segment, and anticipates $10 million more in tariffs for the fiscal year, which could limit earnings growth.
Inflationary Pressures: Inflation contributed to increased costs, negatively impacting margins across segments, including Healthcare and Life Sciences.
Healthcare Segment Margin Decline: EBIT margins for the Healthcare segment decreased by 100 basis points to 24.3%, as benefits from volume, pricing, and restructuring programs were offset by increased tariffs and inflation.
Life Sciences Margin Decline: Margins in the Life Sciences segment declined by 20 basis points due to tariffs and inflation, despite growth in consumables and capital equipment.
Order Decline in Healthcare: Healthcare orders were down 1% year-to-date, attributed to difficult comparisons to the prior year, which could signal potential challenges in sustaining growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Maintaining outlook for fiscal 2026 with approximately 8% to 9% as-reported revenue growth and constant currency organic revenue growth of 7% to 8%.
Earnings Outlook: Earnings per share outlook for fiscal 2026 is $10.15 to $10.30, though the higher end of the range is less likely due to $10 million more in anticipated tariffs.
Free Cash Flow: Expected to be $850 million for fiscal 2026.
Capital Expenditures: CapEx remains unchanged at $375 million for fiscal 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How is the company thinking about fourth quarter constant currency growth?
A:The company is maintaining a 7% to 8% constant currency growth for the year. They anticipate a slowdown in the second half, particularly in AST, due to tough comparisons with last year's strong capital equipment fourth quarter.
Q:What is the status of capital equipment backlog activity in Healthcare and Life Sciences?
A:Life Sciences backlog is showing strong growth due to recovery from a period when pharma wasn't spending much. Healthcare backlog is stable, with strong orders throughout the year, down 1% compared to a blowout year prior.
Q:How are current conditions in the Life Sciences end market and customer conversations around U.S. onshoring and capacity expansions?
A:The company benefits from new capacity demands due to manufacturing location shifts. Recent announcements in states like North Carolina and Pennsylvania for large new processing capacity are positive for the company, especially in aseptic manufacturing.
Q:What are the company's mitigation efforts for the $10 million increase in tariff-related costs?
A:Mitigation efforts include shifting product movement, supplier negotiations, alternative suppliers, cost reductions, and productivity improvements. The $10 million increase is mainly driven by metals and a mix shift to capital equipment sales.
Q:What is the impact of tariffs on the company's fiscal '26 and '27 guidance?
A:The company incurred $16 million in tariffs in the third quarter and expects a slight increase in the fourth. The $55 million annual run rate for fiscal '26 includes tariffs incurred every quarter. Incremental tariff impact in fiscal '27 is expected to be small.
Q:What is the company's view on CMS proposals and their impact on the business?
A:The ASC shift is positive for the company due to new capacity demands and higher clinical support needs. However, there has been no material impact from PPE onshoring or API relocation proposals yet.
Q:What is the company's approach to expanding in EMEA?
A:The company is committed to a more integrated model and competing aggressively in EMEA. Structural changes have been made, but it will take time to fully execute the strategy.
Q:Why hasn't the company been doing more acquisitions recently?
A:The company has been active in smaller bolt-on acquisitions but has not found major transformative M&A opportunities that meet their financial criteria and add customer value.
Q:Why didn't the company raise its cash flow guidance despite strong performance?
A:The company is confident in its guidance but remains conservative due to potential timing fluctuations in the fourth quarter, including weather-related impacts.
Q:What is the company's outlook for fiscal '27 growth?
A:The company sees no significant downside in the market and expects to maintain its typical 7-11% growth algorithm. Detailed guidance will be provided next quarter.
Q:What caused the fluctuation in AST services growth in the December quarter?
A:The quarter started weak in October, improved in November, and was strong in December. There is no specific geographic or customer subsegment explanation, but some customers may have built ahead of tariffs, causing slight inventory adjustments.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the impact of CMS proposals related to PPE onshoring and API relocation, stating they have not seen material commitments or impacts yet. Additionally, they did not provide a clear explanation for the fluctuation in AST services growth in the December quarter, attributing it to general softness without specific reasons.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Accounting Officer
CFO Chief
Chief Accounting
Communications today
Conference Instructions
Corporate Communications
Instructions event
Ms Winter
Officer pleasure
President Investor
Relations maam
Winter Vice
capital spending
caution VP
change mix
day STERIS
decline decrease
decline margin
decrease change
definition press
development share
discipline tax
expenditure month
expense discipline
flow month
improvement increase
increase Capital
increase capital
maam STERIS
margin expense
measure Vice
mix income
month depreciation
month improvement
point decline
productivity volume
rate decline
spending remark
today Senior
volume tariff
STE Transcript
STERIS plc (STE) Q4 2026 Earnings Call Transcript
Positive5-12
The earnings call highlights strong financial performance with expanded EBIT margins and double-digit EPS growth. The Q&A session reveals operational improvements and strategic moves like the $1 billion buyback and tuck-in M&A, suggesting future growth. Despite some challenges, such as tough comps and weather impacts, management's optimistic guidance and strategic investments in high-margin areas indicate a positive outlook. The sentiment is further bolstered by the commitment to shareholder returns and operational efficiencies, supporting a positive stock price movement prediction.
STERIS plc (STE) Q3 2026 Earnings Call Transcript
Positive2-5
The earnings call reveals solid financial performance, with increased revenue and improved EBIT margins in key segments. Despite some margin declines due to tariffs, the overall outlook remains optimistic, supported by strong growth in Life Sciences and AST. The Q&A section highlights effective mitigation strategies for tariffs and positive market trends, such as capacity expansions. The increase in earnings and free cash flow guidance further supports a positive sentiment. However, the lack of major M&A and conservative cash flow guidance slightly temper the outlook, leading to a positive but not strong positive prediction.
STERIS plc (STE) Q2 2026 Earnings Call Transcript
Positive11-6
The earnings call reflects strong financial performance with a 15% increase in EPS and robust free cash flow. The company anticipates 8-9% revenue growth and maintains strong growth across segments. Positive factors include increased EBIT margins and solid growth in healthcare and AST services. Despite headwinds from tariffs and inflation, the guidance remains optimistic, supported by strategic expansions and stable demand. The Q&A session reinforced management's confidence in sustained growth, though some responses lacked detail. Given these factors, a positive stock price movement is expected.
STERIS plc (STE) Q1 2026 Earnings Call Transcript
Positive8-7
The earnings call indicates strong financial performance with increased net income, free cash flow, and dividends. Despite tariff challenges, the company maintains growth expectations and reports strong order growth across segments. The Q&A reveals confidence in market positions and future prospects, with no major concerns raised by analysts. The positive sentiment is supported by organic revenue growth, margin improvements, and strategic cash management plans, suggesting a likely stock price increase in the short term.
STE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
